Cantor Fitzgerald Forecasts CVRx FY2025 Earnings

CVRx, Inc. (NASDAQ:CVRXFree Report) – Cantor Fitzgerald issued their FY2025 earnings estimates for shares of CVRx in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn expects that the company will post earnings of ($1.58) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $14.00 target price on the stock. The consensus estimate for CVRx’s current full-year earnings is ($2.61) per share.

CVRx (NASDAQ:CVRXGet Free Report) last announced its earnings results on Tuesday, October 29th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.12). The business had revenue of $13.37 million for the quarter, compared to analysts’ expectations of $13.28 million. CVRx had a negative net margin of 123.75% and a negative return on equity of 89.06%. During the same quarter last year, the business earned ($0.43) EPS.

Other analysts have also recently issued research reports about the stock. Canaccord Genuity Group upped their price objective on shares of CVRx from $17.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, December 9th. Lake Street Capital raised their price objective on shares of CVRx from $12.00 to $15.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. William Blair raised shares of CVRx from a “market perform” rating to an “outperform” rating in a research note on Tuesday, January 14th. Craig Hallum upped their price objective on CVRx from $20.00 to $22.00 and gave the company a “buy” rating in a report on Friday, January 17th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $16.00 price target (up previously from $13.00) on shares of CVRx in a research note on Wednesday, October 30th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, CVRx currently has an average rating of “Moderate Buy” and an average target price of $17.00.

View Our Latest Analysis on CVRx

CVRx Stock Performance

NASDAQ CVRX opened at $18.13 on Wednesday. CVRx has a 1-year low of $6.40 and a 1-year high of $29.23. The company has a debt-to-equity ratio of 0.76, a current ratio of 11.32 and a quick ratio of 10.23. The stock’s 50 day simple moving average is $14.35 and its 200-day simple moving average is $11.29. The company has a market cap of $439.83 million, a PE ratio of -6.71 and a beta of 1.26.

Institutional Investors Weigh In On CVRx

Hedge funds have recently added to or reduced their stakes in the business. Barclays PLC increased its stake in shares of CVRx by 312.5% during the third quarter. Barclays PLC now owns 19,067 shares of the company’s stock worth $169,000 after buying an additional 14,445 shares during the period. Geode Capital Management LLC grew its position in shares of CVRx by 2.2% during the third quarter. Geode Capital Management LLC now owns 295,124 shares of the company’s stock worth $2,600,000 after acquiring an additional 6,443 shares during the last quarter. XTX Topco Ltd acquired a new position in CVRx in the third quarter valued at $150,000. Jane Street Group LLC raised its stake in CVRx by 36.1% during the 3rd quarter. Jane Street Group LLC now owns 19,038 shares of the company’s stock valued at $168,000 after acquiring an additional 5,053 shares during the last quarter. Finally, State Street Corp raised its stake in shares of CVRx by 11.4% during the third quarter. State Street Corp now owns 264,733 shares of the company’s stock worth $2,332,000 after purchasing an additional 27,071 shares during the last quarter. 75.27% of the stock is currently owned by institutional investors and hedge funds.

About CVRx

(Get Free Report)

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.

Featured Articles

Earnings History and Estimates for CVRx (NASDAQ:CVRX)

Receive News & Ratings for CVRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx and related companies with MarketBeat.com's FREE daily email newsletter.